Company Analysis
Sign in

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE: MTNB · Pharmaceutical Preparations · Bedminster, NJ · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.4
◀ Past 4.6● Present 2.9▶ Future 5.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Matinas BioPharma Holdings, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
25
since 2001, to Dec 31, 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'14'17'18'20'21'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
MATINAS BIOPHARMA INC. a subsidiary
US, as the owner printed on each patent
2 granted
14 published
MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. a subsidiary
US, as the owner printed on each patent
6 granted
1 published
Matinas BioPharma, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 9, 202512,409,227Cochleates made with soy phosphatidylserinePharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Apr 23, 202411,964,019Cochleates made with soy phosphatidylserinePharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Jul 19, 202211,389,407Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agentPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Sep 21, 202111,123,295Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infectionsPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Jul 21, 202010,716,860Cochleates made with soy phosphatidylserinePharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Aug 28, 201810,058,521Omega-3 pentaenoic acid compositions and methods of usePharmaceuticalsMATINAS BIOPHARMA INC.
Oct 3, 20179,775,907Cochleates made with soy phosphatidylserinePharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Dec 9, 20148,906,964Methods of administering compositions comprising docosapentaenoic acidPharmaceuticalsMATINAS BIOPHARMA INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 26, 20242024/0423916ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONSPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Sep 26, 20242024/0316204COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINEPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · patent 12,409,227 granted from it
Oct 6, 20222022/0313717METHODS OF TREATING CRYPTOCOCCUS INFECTIONSPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Dec 23, 20212021/0393526ENCHOLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONSPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Jul 8, 20212021/0205254OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USEPharmaceuticalsMatinas BioPharma, Inc.
Feb 11, 20212021/0038722COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINEPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · patent 11,964,019 granted from it
Apr 23, 20202020/0121601ENCHOLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONSPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · patent 11,123,295 granted from it
Jul 5, 20182018/0185491COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINEPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · patent 10,716,860 granted from it
Jul 5, 20182018/0185308COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE OR CONDITIONSPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Jun 7, 20182018/0153807COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIA INFECTIONS AND LUNG DISEASEPharmaceuticalsMATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MTNB · research, not advice